Zoryl M 3mg/500mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This dual mechanism addresses both insulin secretion and insulin resistance, making Zoryl M effective in patients inadequately controlled by diet and exercise alone. The prolonged-release formulation ensures sustained plasma drug levels, promoting better compliance and minimizing gastrointestinal side effects commonly associated with metformin. Zoryl M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as metformin carries a risk of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended during therapy. Zoryl M should not be used in type 1 diabetes or diabetic ketoacidosis. Dose adjustments may be necessary based on therapeutic response and tolerability.